i agree that this stock has great potential, and is safer than most biotechs out there. but with biotechs come extreme volatility in share prices. this stock has made a great run in the last few days but i fear it may be approaching overbought status. Don't be surprised by a pullback (1.10s and 1.20s would not be surprising), especially when QE and debt ceiling news comes out before any breakthrough SBOTF news. Trying to predict the market is foolish of course, but if you believe in the company, you will take advantage of the opportunity and buy the dips.